Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the company. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $7.81.

A number of brokerages have weighed in on ABUS. Wedbush reiterated an “outperform” rating and set a $20.00 target price (up previously from $13.00) on shares of Arbutus Biopharma Corp. in a research report on Friday, August 5th. Leerink Swann lowered shares of Arbutus Biopharma Corp. from an “outperform” rating to a “market perform” rating and set a $5.00 target price for the company. in a research report on Friday, August 5th. Zacks Investment Research lowered shares of Arbutus Biopharma Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. William Blair reiterated an “outperform” rating on shares of Arbutus Biopharma Corp. in a research report on Sunday, August 21st. Finally, Chardan Capital reiterated a “sell” rating on shares of Arbutus Biopharma Corp. in a research report on Sunday, October 2nd.

Arbutus Biopharma Corp. (NASDAQ:ABUS) opened at 2.70 on Wednesday. Arbutus Biopharma Corp. has a 52-week low of $2.45 and a 52-week high of $5.79. The firm’s market capitalization is $148.07 million. The company’s 50-day moving average is $3.06 and its 200-day moving average is $3.69.

Institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can bought a new stake in shares of Arbutus Biopharma Corp. during the second quarter worth $2,822,000. I.G. Investment Management LTD. bought a new stake in shares of Arbutus Biopharma Corp. during the second quarter worth $870,000. Baker BROS. Advisors LP bought a new stake in shares of Arbutus Biopharma Corp. during the third quarter worth $621,000. K2 Principal Fund L.P. increased its stake in shares of Arbutus Biopharma Corp. by 69.3% in the third quarter. K2 Principal Fund L.P. now owns 107,620 shares of the biopharmaceutical company’s stock worth $370,000 after buying an additional 44,070 shares in the last quarter. Finally, Morgan Stanley increased its stake in shares of Arbutus Biopharma Corp. by 34.9% in the third quarter. Morgan Stanley now owns 134,715 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 34,862 shares in the last quarter. Institutional investors own 31.59% of the company’s stock.

Arbutus Biopharma Corp. Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

5 Day Chart for NASDAQ:ABUS

Receive News & Stock Ratings for Arbutus Biopharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp. and related stocks with our FREE daily email newsletter.